Paper
0
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer
Authors
Caitlin McIntyre,Adrien Grimont
Jiwoon Park,Yinuo Meng,Whitney Sisso,Kenneth Seier,Gun Jang,Henry Walch,Victoria Aveson,David Falvo,William Fall,Carlos Chan,Anna Wenger,Brett Ecker,Alessandra Pulvirenti,Rebecca Gelfer,María Zafra,Nikolaus Schultz,Wungki Park,Eileen O’Reilly,Shauna Houlihan,Alicia Alonso,Erika Hissong,George Church,Christopher Mason,Despina Siolas,Faiyaz Notta,Mithat Gönen,Lukas Dow,William Jarnagin,Rohit Chandwani
+29 authors
,Eileen O'ReillyJournal
Published
Aug 1, 2024
Show more
Save
Tip0
TipSave
Abstract
KRAS mutations in pancreatic ductal adenocarcinoma (PDAC) are suggested to vary in oncogenicity but the implications for human patients have not been explored in depth. We examined 1,360 consecutive PDAC patients undergoing surgical resection and find that KRAS
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.